This study aimed at investigating variables affecting amikacin pharmacokinetics in order to propose optimal initial dosing in critically ill adult patients treated with once-daily amikacin regimen. Amikacin pharmacokinetics was calculated based on plasma concentrations using one compartmental analysis. Relationships between pharmacokinetic parameters and demographic/clinical data were explored in linear regression models. Simulated dose and dosing intervals were derived from body size descriptors and estimated creatinine clearances for each patient. Amikacin volume of distribution best correlated with body surface area, while amikacin clearance was best predicted by CKD-EPI creatinine clearance. Our study suggests that dose of 517 mg per m2 of body surface area leads to amikacin levels most approaching target peak concentration. Dosing interval calculated as 228.7 × e-3.08× CKD-EPI creatinine clearance (mL s-1) + 15.84 most closely approximated optimal dosing intervals based on individual pharmacokinetics. The dosing nomogram based on CKD-EPI creatinine clearance was designed.

1st Faculty of Medicine Department of Pharmacology Charles University and General University Hospital Prague Prague 2 Czech Republic

References provided by Crossref.org

Vancomycin population pharmacokinetics and dosing proposal for the initial treatment in obese adult patients

Elimination and penetration of amikacin into urine in patients with decreased glomerular filtration rate

Dose Optimization and Targeting Strategies of Anti-Infective Agents

Ganciclovir Pharmacokinetics and Individualized Dosing Based on Covariate in Lung Transplant Recipients

No Time Dependence of Ciprofloxacin Pharmacokinetics in Critically Ill Adults: Comparison of Individual and Population Analyses

What is the Best Predictor of Phenobarbital Pharmacokinetics to Use for Initial Dosing in Neonates?